share_log

4: Statement of changes in beneficial ownership of securities-Officer Bligh James

4: Statement of changes in beneficial ownership of securities-Officer Bligh James

4:持股變動聲明-高管 Bligh James
美股SEC公告 ·  2024/11/21 05:33

牛牛AI助理已提取核心訊息

Interim CFO of Conduit Pharmaceuticals, Bligh James, has engaged in a transaction involving the company's stock on November 18, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action reflects a change in the holdings of Bligh James, but without further information, the impact on his total number of shares held after the action cannot be determined.
Interim CFO of Conduit Pharmaceuticals, Bligh James, has engaged in a transaction involving the company's stock on November 18, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action reflects a change in the holdings of Bligh James, but without further information, the impact on his total number of shares held after the action cannot be determined.
Conduit Pharmaceuticals的臨時首席財務官Bligh James於2024年11月18日進行了涉及公司股票的交易。公告中未披露交易的具體細節,包括股票數量、股票性質、交易價格和股票的總價值。此舉反映了Bligh James持股的變化,但在沒有進一步信息的情況下,無法確定交易後他持有的總股份數的影響。
Conduit Pharmaceuticals的臨時首席財務官Bligh James於2024年11月18日進行了涉及公司股票的交易。公告中未披露交易的具體細節,包括股票數量、股票性質、交易價格和股票的總價值。此舉反映了Bligh James持股的變化,但在沒有進一步信息的情況下,無法確定交易後他持有的總股份數的影響。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。